Recommended

Amgen secures Uplizna EU approval in gMG
Orsellinic acid study demonstrates production first
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
J&J to site new $1bn cell therapy facility in Pennsylvania
FDA sets new default standard for US drug approvals
Daiichi Sankyo picks new Global Head of R&D
Dr Belén Garijo replaces Paul Hudson as Sanofi CEO
Discover how to harness digital PCR for rapid sterility testing
news

First treatment conditionally licensed for chronic hepatitis D

1
SHARES

Gilead Science’s antiviral medication for chronic hepatitis D has been recommended by the National Institute for Health and Care Excellence (NICE).

First treatment conditionally licensed for chronic hepatitis D

Hepcludex® (bulevirtide) is the first medicine to be conditionally licensed for chronic hepatitis delta virus (HDV) infection in Great Britain”

The National Institute for Health and Care Excellence (NICE) has recommended NHS use of Hepcludex® (bulevirtide). It is the first medicine to be conditionally licensed for chronic hepatitis delta virus (HDV) infection in Great Britain. Gilead Sciences’ antiviral medication is recommended as an option for chronic hepatitis D.

 

SPACES ARE FILLING FAST – SECURE YOURS!


Rapid sterility testing is no longer optional for advanced therapies – it’s becoming operationally essential. Join this webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing

18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

The session will discuss future trends in sterility testing and showcase successful rapid sterility testing in cell and gene therapy products, demonstrating practical applications and benefits.

Register now to join live or for free access to the on-demand recording if you can’t make the date

Indicated to treat the most aggressive form of viral hepatitis, bulevirtide is for adults with compensated liver disease only if there is evidence of significant fibrosis and their hepatitis has either not responded to peginterferon alfa-2a (PEG-IFN) or they cannot have interferon-based therapy. Bulevirtide can be self-administered at home with a once-daily injection.  

A regulatory first

Historically, “there have been no licensed treatment options available for NHS patients [with chronic hepatitis D] in England and Wales,” stated Dr Ahmed Elsharkawy, Consultant Transplant Hepatologist and Honorary Senior Clinical Lecturer at the University of Birmingham. Delivered via subcutaneous injection, the peptide-based therapy can target a virus that can be “life-threatening as it causes serious liver damage and liver cancer,” according to Dr Elsharkawy.

NICE’s conditional authorisation of Gilead’s chronic hepatitis D treatment

The conditional marketing authorisation was granted based on the results of two Phase II studies, MYR202 and MYR203. Additional efficacy and safety data is being evaluated in the ongoing MYR301 Phase III study.

The NICE recommendation applies to the NHS in England. However, it is expected that the NHS in Wales will follow this guidance within the coming 60 days.

SMC accepts treatment for chronic hepatitis delta virus

HDV infection is relatively rare. It is estimated that around 1,800 people in England have evidence of HDV infection. Cirrhosis, liver cancer and death within 5-10 years can occur as a result, according to NICE and Gilead.

 
Share via
Share via